Checkmate Pharmaceuticals, Inc. (CMPI)

$10.5

0.00 (0.00%)
Rating:
Recommendation:
-
Symbol CMPI
Price $10.5
Beta 0.000
Volume Avg. 0.23M
Market Cap 227.123M
Shares () -
52 Week Range 2.0-10.5
1y Target Est -
DCF Unlevered CMPI DCF ->
DCF Levered CMPI LDCF ->
ROE -83.92% Strong Sell
ROA -94.32% Strong Sell
Operating Margin -
Debt / Equity 21.71% Neutral
P/E -
P/B 4.13 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CMPI news


Mr. Barry A. Labinger
Healthcare
Biotechnology
NASDAQ Global Market

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.